pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-452 |
Genomic Coordinates | chrX: 151959628 - 151959712 |
Synonyms | MIRN452, hsa-mir-452, MIR452 |
Description | Homo sapiens miR-452 stem-loop |
Comment | The mature sequence shown here represents the most commonly cloned form from large-scale cloning studies . The 5' end of the miRNA may be offset with respect to previous annotations. |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-452-3p | ||||||||||||||||||
Sequence | 58| CUCAUCUGCAAAGAAGUAAGUG |79 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Array-cloned | ||||||||||||||||||
Editing Events in miRNAs |
|
||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ATXN7 | ||||||||||||||||||||
Synonyms | ADCAII, OPCA3, SCA7 | ||||||||||||||||||||
Description | ataxin 7 | ||||||||||||||||||||
Transcript | NM_000333 | ||||||||||||||||||||
Other Transcripts | NM_001128149 , NM_001177387 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ATXN7 | |||||||||||||||||||||
3'UTR of ATXN7 (miRNA target sites are highlighted) |
>ATXN7|NM_000333|3'UTR 1 CAGCTGAAAATAGCACGGGGAGGAATAATGCGGACACTTTTGAGGACAAGTTACACCTCCACTCAGCACTCTGGACTCCA 81 CGATGCCTTTGAGTCTGTTTTCCCAACCTCCTGTGGGCCTCAAGGGTAGAAACCTGCCGGGCTGTTGTTTTAACGAGGAT 161 TTCCCTGAAGCTATGTCTCTAGCAGTGAGTACTCATAAAGGACACTGGATCAAGTTCAGCCACCGAATTGCTTTTATCAG 241 TGTTAAAGTGGTCTGAACTGCTTGCTACCAATCTGTGAGAAGTTTTTGTTTTTGTTTTGTTTTTTAACTTGCAGTATATC 321 ACAGAGCCACTCTTCAAGTAGATTGGCTGGGCAAAAGAATGTTTTGGCAAGAGCGTTACTGTAGACCTTTCTCCCTCCTT 401 CCTTTTACTACCATTTTTTTTTAACACTGTCATCTGTAGGTCACTCTCCAGCAGTTAGGCACCTTAACTGGAGACCAGAA 481 ACCTTCCAGAGAACACAGGGCTGCATCCCGAGCAACCCTCTGAAGAAGGGAATTAGGCTTTAGATTTTGATAGCAATGTT 561 CCAGGAATGAAATATAGATGTTAGCCCAAGACACCATGACAAAATAGCCCAGCCTTTTGAGAGTAATTTGGGAAAAGAAG 641 CTGTCAGAAGTTTCTAACTTACAAACTGGTTTGAAATTTTTGATGCCCAGACAGCAAGTATAAATCATTTTGGAGGCTTA 721 CTTTTCATGATACAAAAGCAATTCTGTGTGATTTTTTTTTTTAAGAAGAAAGAAAATGCAAGCTAGTTTTGAGAAAGGAA 801 GGCCAAATTGGGTCGGGGGAGGGTGGGAGTGAGGAAGTTAAAATCACTATAGGGAGAAAAAACTTTTTTCAAGATTTCCA 881 AAGAGATGAAATTTTCTTAATCCTTTTAAGTTTTCATAGTAAACAGTATGGCAGATTGGGTTGGTTGTCCTACCTGGTCT 961 ATTTTTAAAAGTCACCTTTTAAAGTGACATTATTAGATACACTTAAATGTTTCCAAGGCACTCTCTACATTACCCTTGTT 1041 TTTCTCTTTGGATACTGTCCTGGGACTAAGTGTAGATTTCTGCTTCAAGCACTTCTGGCATTGTGTGTTTTTGTATGCAC 1121 TCCCCTTCATGCCACTTCAGATGTTTATTTGGATGTGGTTGGGGACGAGAGCAGACACCAAGGAAAGGGAGTTGGAGAGA 1201 ATGTAAGTCCTGACCTGAAGGTCTTTTGTGATGCATGTATAGGATTGCCCTGACACACACCCTCCTTTCTTGGGATTATA 1281 CCAGCCATCTTCCTGAGAGTTTTGGAGCCCTCTAGGATATTTTTTCTAGTACCCCACCCCCCACCCCTAAAGAAAGACCT 1361 TAATATGTTAAAACAGCATTGCTTGGAGAAGGTGTCATTGAATTCCGGGACGAGCCGGAGCCTTTAAATGGGTGCTTCCA 1441 CCACTACAGGCTCCTGACACGAGTAACAGGCACTGTTGCTTAGAAGAACACACGAAGTTGCCGAACACAGGGTAAAATTT 1521 CCAAGGCGCTGATCGTTGCCCTGGCCAGGGCCTGATGAGAGCCAGTCAGTACATTCTTTTTTTCCTACAGTTCTTGGGTT 1601 TCAAACTTCAGTTTCAGGGAATTTCAAGTCAACAACAGGTAGAATGAATAAACTTGGTTACCAGCCTAATAATGTGAATT 1681 GCTACAGAATTATTCTTATTATGTAAGAAAACAAAAACTTTATGCAGATACTTTAGCTATAAATTGATGTAAAATACTGA 1761 TTTTTTTAAAGGAAGGAGAGAACAGTATCTTGTTCAATTATTATGCAATCAATCAGTAAATGTTTTTAAAATGATACTAC 1841 AGGAGAGCTTAGTAAGGAGAGGGCATGGATGGGCCAGTTTGGCATAGTTGGGAGAAATCAGTCTGGTTTCCATCCCAGTC 1921 GGGGAAGAGAGAGGTGAGAGGGAATCAGAACGTACCTAGTTGATTCCTTGGTGACAAGTGCAATGGGGTATGGGTAGAAT 2001 TTATTTTCAGAGCCAAGAGGACTTGATGGTTATAAATAAAGTTGCCTTTAGCAATGGAATTTACAGATCGATCATGTTGT 2081 TCCGAAAGATGTGAATAGGATCCACAATAACAAGTTGATTCAGACTAATGTAGATATTTAGATTAGCAAGTATTGAACAT 2161 TTGATTTCTTAGACTGAGGTTTTAAATGAATTTCATTATTTCTCCCGGTAATACACAGAGCATCGGGATTAGGAAATTAG 2241 CCATTTTGGATTCTGTCTGCCACAAACAGACCTATTCTAAACAGTGCTATTAAATTTTAGACTGTTGTTCAAATATTTTA 2321 TTTTCTCCTAAACTACTTTTTATGGTGATGAATAATTAAGACCATTTAAAACACGGGAGTACAAGTATTTTTTTGAATTA 2401 AATTAACTTGCAAAAACCAAATTTGCAGTGGTTGGGTTGTTTCTAGACAGACTTTGGTATCAATTTAAAACCAAGATAAT 2481 TTTTATATTCTTTCCAATAGAATTTCATGACAACTCCTGCAGTTTTCTTAACCTACAAAAAAAAAAAAAAAGTGCTGCAA 2561 TGATGAACAAAGAATTATACAAAACCTACTTTTGTATCTTTATTTTGGAATTTCTTGTTCTATTATAAATATGGAAGTAT 2641 CCCTATTTCAGAAGACATATTTTGTTAAAAATGAATTGTACATATTTAAATATGTATTTTTGCACAGGTCTTTTTTTCTG 2721 ATATCCTGTTTTGGTACAATTGAGATCATCTAGTATTTATTTATTAATTAATAAAAGTAAATACCTTTTTATAATTTGAA 2801 GTGGTTCACTGCCAAGCCAATAGTTCTAGAACCTGCCTCCTTTACAGTTTTAAGGGATGCCTCTGTTCTGTGAAAAGTCT 2881 TTGTCCCTTTTAGTGTCTCGGGAGTGGATTCATACAGATGAAGTGGGCATTGCTTCTTCCTGGTTGCCTGGTTTCCCGAT 2961 AGACTACATGTAACTAAGTGACACACTGCTTTTCTTTTGTTAGTATTTTATGTGTGGGAGTATGTGACTGCGTGTGTGTG 3041 TGCCTGTGCGTGTGTGTGTATACTCAGCACATGTATGTTACTATGTGATGTGGTTTAAAACTAATGGAAAAAACTGAAAG 3121 TGCCTGAAACTAGTTTTAAGCTTAGACAGAATCTCTTTAAAAAGACTTGAATGTTCAGTTGAACTTTTGGAGTTTGCTTT 3201 TTCCACCTAAATATTGTTTCTAAAATTTTAGGGGCGGAGTTGAAAACCACCAATGCTGGTAATTTTATAAGGTATTTTAA 3281 AATTAAGACCTCTTGGTTCATAGTAATTCAATTGGTGATGGATTGCCTGGTGGCACCAAGGGTTACAGATCTTTTTGTCA 3361 GCCAGCAACTTACACGATGTGTCCGTTTTGTTATTCACTCATGAAATACAATTTAAAATATTTAAAATATTTTGTATTCC 3441 AAAAATATAATACAAAGAAGTACCTCTGAGAACATTGAAAAAAATGTATAATTTGAAAAATGTAACTTATAAGGGCAGCT 3521 GTCTTCCTGCAAGAGTTCTGTTGCCAAGGAATTTCTTAATGTCGCTCATTCTGTCCAGGGGGTTTGGGGCGATTGGGCTT 3601 TGAAAAAATATTCTTAAAAGTTTGTTTAGCAGAAAATAATCACTTTTACATTTTGTGCAAAACATTTTACATTTTCAGAT 3681 AATTTAAATGAGCACTACATACTGTCAGTGTGAATGTAGGGCCTTGAAAGCATTTTGCTTTTTTTTTTTTTTTTTTTTTT 3761 TTGAGCTTGGTTATAAAAGCAATCTCCTGTGTTAAAAACGTGTGAATAGTTTGATAATTTGTACACATAATCAAGAGCAT 3841 CTCAGCTGGACTTTGTGTTGGCTGCTGTATAGAACATGAACAAATGTCAAGGGATAGAAAATTACTTTGGATATTTAAAA 3921 GAGAAGAAATATATAGTCTATTTGTTTTGTAACAAGTTTCTGTAAATAAAATAATTTATACTATTTATAAGAAAAAAAAA 4001 AAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | BC-1 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM796038. RNA binding protein: AGO2. Condition:4-Thiouridine
... - Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe. |
Article |
- Gottwein E; Corcoran DL; Mukherjee N; et al. - Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
|
CLIP-seq Support 1 for dataset GSM796038 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-1 / 4-Thiouridine |
Location of target site | ENST00000295900.6 | 3UTR | UCAAGAUUUCCAAAGA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
87 hsa-miR-452-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT150000 | MIDN | midnolin | 2 | 10 | ||||||||
MIRT330600 | ZWINT | ZW10 interacting kinetochore protein | 2 | 2 | ||||||||
MIRT358701 | SUB1 | SUB1 homolog, transcriptional regulator | 2 | 4 | ||||||||
MIRT362854 | EIF4H | eukaryotic translation initiation factor 4H | 2 | 2 | ||||||||
MIRT447215 | ATXN7 | ataxin 7 | 2 | 2 | ||||||||
MIRT466655 | TAF1D | TATA-box binding protein associated factor, RNA polymerase I subunit D | 2 | 6 | ||||||||
MIRT483979 | PANK1 | pantothenate kinase 1 | 2 | 8 | ||||||||
MIRT485118 | SF3B3 | splicing factor 3b subunit 3 | 2 | 2 | ||||||||
MIRT488864 | AUTS8 | Autism, susceptibility to, 8 | 2 | 2 | ||||||||
MIRT492293 | SH2B3 | SH2B adaptor protein 3 | 2 | 2 | ||||||||
MIRT492976 | NCK2 | NCK adaptor protein 2 | 2 | 2 | ||||||||
MIRT497410 | LRRC40 | leucine rich repeat containing 40 | 2 | 2 | ||||||||
MIRT511143 | MRPL17 | mitochondrial ribosomal protein L17 | 2 | 6 | ||||||||
MIRT512650 | MAP3K2 | mitogen-activated protein kinase kinase kinase 2 | 2 | 2 | ||||||||
MIRT513017 | NSFL1C | NSFL1 cofactor | 2 | 6 | ||||||||
MIRT520445 | TSPAN2 | tetraspanin 2 | 2 | 6 | ||||||||
MIRT527995 | NDNF | neuron derived neurotrophic factor | 2 | 2 | ||||||||
MIRT528667 | PDE4DIP | phosphodiesterase 4D interacting protein | 2 | 2 | ||||||||
MIRT533512 | TRIM71 | tripartite motif containing 71 | 2 | 2 | ||||||||
MIRT537404 | FBXO47 | F-box protein 47 | 2 | 2 | ||||||||
MIRT538161 | DCP2 | decapping mRNA 2 | 2 | 2 | ||||||||
MIRT539124 | ARHGEF17 | Rho guanine nucleotide exchange factor 17 | 2 | 2 | ||||||||
MIRT540666 | MIS18A | MIS18 kinetochore protein A | 2 | 4 | ||||||||
MIRT542948 | GDF11 | growth differentiation factor 11 | 2 | 2 | ||||||||
MIRT547534 | MAML3 | mastermind like transcriptional coactivator 3 | 2 | 2 | ||||||||
MIRT559033 | C20orf24 | chromosome 20 open reading frame 24 | 2 | 4 | ||||||||
MIRT559554 | ARF6 | ADP ribosylation factor 6 | 2 | 2 | ||||||||
MIRT570177 | RCBTB1 | RCC1 and BTB domain containing protein 1 | 2 | 2 | ||||||||
MIRT573149 | ITGA9 | integrin subunit alpha 9 | 2 | 2 | ||||||||
MIRT575849 | Rab1 | RAB1A, member RAS oncogene family | 1 | 1 | ||||||||
MIRT611034 | RRP1B | ribosomal RNA processing 1B | 2 | 2 | ||||||||
MIRT616281 | HMGB1 | high mobility group box 1 | 2 | 2 | ||||||||
MIRT618372 | PRKG2 | protein kinase, cGMP-dependent, type II | 2 | 2 | ||||||||
MIRT619540 | PIWIL2 | piwi like RNA-mediated gene silencing 2 | 2 | 2 | ||||||||
MIRT622303 | SGIP1 | SH3 domain GRB2 like endophilin interacting protein 1 | 2 | 2 | ||||||||
MIRT622590 | PRRG4 | proline rich and Gla domain 4 | 2 | 2 | ||||||||
MIRT624441 | CAMK2N1 | calcium/calmodulin dependent protein kinase II inhibitor 1 | 2 | 2 | ||||||||
MIRT637089 | KLRD1 | killer cell lectin like receptor D1 | 2 | 2 | ||||||||
MIRT639084 | ADCYAP1 | adenylate cyclase activating polypeptide 1 | 2 | 2 | ||||||||
MIRT639334 | NINJ1 | ninjurin 1 | 2 | 2 | ||||||||
MIRT639798 | EIF3E | eukaryotic translation initiation factor 3 subunit E | 2 | 2 | ||||||||
MIRT640851 | RAB3B | RAB3B, member RAS oncogene family | 2 | 2 | ||||||||
MIRT641628 | KIAA1244 | ARFGEF family member 3 | 1 | 1 | ||||||||
MIRT642634 | EPPIN | epididymal peptidase inhibitor | 2 | 2 | ||||||||
MIRT643053 | EPPIN-WFDC6 | EPPIN-WFDC6 readthrough | 2 | 2 | ||||||||
MIRT643416 | ERVMER34-1 | endogenous retrovirus group MER34 member 1, envelope | 2 | 2 | ||||||||
MIRT645586 | SAR1A | secretion associated Ras related GTPase 1A | 2 | 2 | ||||||||
MIRT647393 | FAM181B | family with sequence similarity 181 member B | 2 | 2 | ||||||||
MIRT649411 | CDC14B | cell division cycle 14B | 2 | 2 | ||||||||
MIRT649477 | CLDN16 | claudin 16 | 2 | 2 | ||||||||
MIRT651307 | ZDHHC20 | zinc finger DHHC-type containing 20 | 2 | 2 | ||||||||
MIRT651387 | ZBTB16 | zinc finger and BTB domain containing 16 | 2 | 2 | ||||||||
MIRT653411 | SLC7A2 | solute carrier family 7 member 2 | 2 | 2 | ||||||||
MIRT654084 | RSPH4A | radial spoke head 4 homolog A | 2 | 2 | ||||||||
MIRT654613 | PTPRM | protein tyrosine phosphatase, receptor type M | 2 | 2 | ||||||||
MIRT655338 | PCP4L1 | Purkinje cell protein 4 like 1 | 2 | 2 | ||||||||
MIRT656173 | MRPL44 | mitochondrial ribosomal protein L44 | 2 | 2 | ||||||||
MIRT657272 | HS3ST3B1 | heparan sulfate-glucosamine 3-sulfotransferase 3B1 | 2 | 2 | ||||||||
MIRT657881 | GFPT1 | glutamine--fructose-6-phosphate transaminase 1 | 2 | 2 | ||||||||
MIRT659875 | CAPRIN1 | cell cycle associated protein 1 | 2 | 2 | ||||||||
MIRT662381 | ICA1L | islet cell autoantigen 1 like | 2 | 4 | ||||||||
MIRT666308 | SLC22A3 | solute carrier family 22 member 3 | 2 | 2 | ||||||||
MIRT667274 | NAV1 | neuron navigator 1 | 2 | 2 | ||||||||
MIRT667614 | LIMCH1 | LIM and calponin homology domains 1 | 2 | 2 | ||||||||
MIRT674242 | NUP62 | nucleoporin 62 | 2 | 4 | ||||||||
MIRT690386 | PARP15 | poly(ADP-ribose) polymerase family member 15 | 2 | 2 | ||||||||
MIRT693402 | NUDT16 | nudix hydrolase 16 | 2 | 2 | ||||||||
MIRT702503 | KDELR1 | KDEL endoplasmic reticulum protein retention receptor 1 | 2 | 2 | ||||||||
MIRT708632 | STMN4 | stathmin 4 | 2 | 2 | ||||||||
MIRT708839 | SCAND3 | zinc finger BED-type containing 9 | 1 | 1 | ||||||||
MIRT709016 | HSBP1 | heat shock factor binding protein 1 | 2 | 2 | ||||||||
MIRT709235 | RANGAP1 | Ran GTPase activating protein 1 | 2 | 2 | ||||||||
MIRT710885 | PARL | presenilin associated rhomboid like | 2 | 2 | ||||||||
MIRT712262 | PPP1CB | protein phosphatase 1 catalytic subunit beta | 2 | 2 | ||||||||
MIRT712573 | ATP2B4 | ATPase plasma membrane Ca2+ transporting 4 | 2 | 2 | ||||||||
MIRT715046 | PRPF38A | pre-mRNA processing factor 38A | 2 | 2 | ||||||||
MIRT718905 | GALR1 | galanin receptor 1 | 2 | 2 | ||||||||
MIRT719368 | FEM1A | fem-1 homolog A | 2 | 2 | ||||||||
MIRT719495 | SEC24B | SEC24 homolog B, COPII coat complex component | 2 | 2 | ||||||||
MIRT719601 | PRKX | protein kinase, X-linked | 2 | 2 | ||||||||
MIRT719891 | RRP36 | ribosomal RNA processing 36 | 2 | 2 | ||||||||
MIRT720063 | ZNF449 | zinc finger protein 449 | 2 | 2 | ||||||||
MIRT721679 | CMTM4 | CKLF like MARVEL transmembrane domain containing 4 | 2 | 2 | ||||||||
MIRT721724 | VTI1A | vesicle transport through interaction with t-SNAREs 1A | 2 | 2 | ||||||||
MIRT723370 | ZNF470 | zinc finger protein 470 | 2 | 2 | ||||||||
MIRT724941 | TXNL1 | thioredoxin like 1 | 2 | 2 | ||||||||
MIRT725302 | NLRC5 | NLR family CARD domain containing 5 | 2 | 2 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|